NCT06248411View on ClinicalTrials.gov

A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

169

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

October 31, 2029

Study Completion Date

April 30, 2030

Conditions
Advanced or Metastatic Solid Tumors
Interventions
DRUG

KK2260

KK2260 will be administered intravenously at several dose levels, and after determining MTD, multiple dose regimens will be evaluated in multiple cancer types to target.

DRUG

KK2260

KK2260 will be administered intravenously at several dose levels, and after determining MTD, multiple dose regimens will be evaluated in multiple cancer types to target.

Trial Locations (7)

464-8681

RECRUITING

Aichi Cancer Center Hospital, Nagoya

277-8577

RECRUITING

National Cancer Center Hospital East, Kashiwa

650-0017

RECRUITING

Kobe University Hospital, Kobe

411-8777

RECRUITING

Shizuoka Cancer Center, Nagaizumi-cho

104-0045

RECRUITING

National Cancer Center Hospital, Chuo-ku

135-8550

RECRUITING

The Cancer Institute Hospital of JFCR, Koto-ku

540-0008

RECRUITING

Osaka International Cancer Institute, Osaka

All Listed Sponsors
lead

Kyowa Kirin Co., Ltd.

INDUSTRY